How should a patient with a tree nut allergy be evaluated and managed?

Tree Nut Allergy: Evaluation and Management

Patients with suspected tree nut allergy should undergo diagnostic confirmation through skin prick testing (SPT) and specific IgE (sIgE) testing, with component-resolved diagnostics (CRD) to identify high-risk patients, followed by oral food challenges (OFC) when diagnosis remains uncertain—while management centers on strict avoidance of confirmed allergens, prescription of epinephrine auto-injectors, and education about anaphylaxis recognition and treatment. 1

Diagnostic Approach

Initial Evaluation

Obtain a detailed history focusing on:

• Timing and nature of reactions (immediate onset suggests IgE-mediated allergy)
• Specific tree nuts involved (walnut, cashew, hazelnut, almond, pistachio, pecan, macadamia, brazil nut)
• Severity of previous reactions (urticaria, angioedema, respiratory symptoms, anaphylaxis)
• Reproducibility of symptoms with repeated exposures 2

Diagnostic Testing

First-line testing includes:

• Skin prick tests (SPT) using standardized tree nut extracts
• Serum specific IgE (sIgE) measurements 2, 1

Advanced diagnostic tools that improve specificity:

• Component-resolved diagnostics (CRD): Testing for storage proteins significantly increases diagnostic accuracy 3, 4
  • Cor a 14 and Cor a 9 for hazelnut
  • Jug r 1 for walnut
  • Ana o 3 for cashew
• Basophil activation test (BAT): Shows superior specificity compared to sIgE and SPT, though currently limited to research settings 2, 3

Oral Food Challenges

OFCs remain the gold standard for confirming diagnosis or evaluating tolerance 2, 1. Key considerations:

• Use standardized protocols with appropriate clinical setting based on risk stratification
• High-risk challenges (higher sIgE/SPT values) should occur in infusion centers with immediate epinephrine access
• Low-risk challenges can be performed in outpatient settings 2
• Most useful when SPT/sIgE results are equivocal or to confirm tolerance

Understanding Co-Reactivity

Critical pitfall: Most patients sensitized to multiple tree nuts are NOT allergic to all of them 5.

• Over 50% of patients sensitized to 5-6 tree nuts are actually allergic to only 1-2 5
• Walnut and cashew show highest allergy rates (75% and 66% respectively in sensitized patients) 5
• Important co-allergy patterns:
  • Two-thirds of walnut-allergic patients are also allergic to pecan
  • Two-thirds of cashew-allergic patients are also allergic to pistachio
  • ALL pecan-allergic patients are allergic to walnut
  • ALL pistachio-allergic patients are allergic to cashew 5

Therefore, blanket avoidance of all tree nuts is generally NOT required—selective introduction of tolerated nuts improves quality of life 3, 5.

Management Strategy

Allergen Avoidance

• Strict avoidance of confirmed allergen(s) only—not all tree nuts unless proven allergic 1
• Educate about cross-contamination risks when eating outside the home 4
• Provide clear written instructions on reading food labels

Emergency Preparedness

Epinephrine is the first-line treatment for anaphylaxis 2, 1:

• Prescribe epinephrine auto-injector to all confirmed tree nut allergic patients
• Provide two devices (home and school/work)
• Train patient and caregivers on proper administration technique
• Instruct to administer at first sign of systemic reaction, then call 911
• Emphasize routine checking of expiration dates 1

Follow-Up Care

Implement the SAFE mnemonic 1:

• Seek support: Counsel about risk of repeat episodes
• Allergen identification: Verify specific triggers through testing
• Follow-up: Refer to allergist/immunologist for ongoing management
• Epinephrine: Ensure prescription and education before discharge

Emerging Therapeutic Options

Oral immunotherapy (OIT) is the most studied disease-modifying approach 6, 7:

• Single-nut or multi-nut protocols show effectiveness in conferring protection from accidental exposures
• Can be combined with omalizumab for enhanced safety
• Omalizumab monotherapy is the only FDA-approved alternative for reducing reactions from accidental exposure 6

Other investigational approaches include sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), though data remain limited 6.

Special Considerations

Peanut-Allergic Children and Tree Nut Introduction

For peanut-allergic children considering tree nut introduction 8:

• 23-68% have co-existent tree nut allergy
• No fatalities reported on first ingestion in infancy
• Pre-emptive screening risks overdiagnosis and delayed introduction
• Recommend direct introduction at home for most infants, reserving screening for families with high anxiety or previous severe reactions

Prognosis

Tree nut allergy is typically lifelong with low resolution rates 7, 4, making accurate initial diagnosis and appropriate management education essential for long-term safety and quality of life.